Antisense oligonucleotides as a potential therapeutic strategy in hypertrophic cardiomyopathy caused by MYBPC3 variants

13 April 2024 (08:30 - 17:40)

Organised by:

Abstract

Sign in to view the resources

About the speaker

Miss Serena Munteanu

Biomedical Research Institute of Murcia (IMIB-Arrixaca), El Palmar, Murcia (Spain)

72 More presentations in this session

Presentation thumbnail

Characterization of senescence in human cardiac fibroblasts

Doctor A. Costa (Genoa, IT)

Presentation thumbnail

Cardioprotective effect of cemtirestat treatment in male Zucker diabetic fatty rats: a pilot study.

Doctor T. Egan Benova (Bratislava, SK)

Presentation thumbnail

Dynamic links between the cardiac intermediate filaments of the cytoskeleton and nucleoskeleton for proper cardiomyocyte differentiation, maturation and reprogramming.

Doctor M. Tsikitis (Athens, GR)

Presentation thumbnail

Differential sex-dependent role of lncRNAs in cardiomyopathy

Professor D. Franco (Jaen, ES)

Presentation thumbnail

MiR-92b-3p modulates apoptosis in smooth muscle cells through BCL2L11 regulation, unravelling novel therapeutic strategies for unstable plaques.

Mr J. Koester (Halle, DE)

Access the full session

Session thumbnail

Poster session 2

The Event

Event poster

Frontiers in CardioVascular Biomedicine 2024

13 April 2024 08:30 CET

You may be interested in

Congress Presentation

An antisense lncRNA mediated mechanism controls desmoplakin gene expression

Congress Presentation

MYBPC3 genotypes associated with familial hypertrophic cardiomyopathy

Congress Presentation

Understanding the aetiology of HCM and pathways for intervention

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources